Orchard Therapeutics

MA - BostonBiotechnology1 H-1B visas (FY2023)

Focus: Orchard Therapeutics is a publicly traded biotech company focused on ex-vivo autologous hematopoietic stem cell gene therapy for rare genetic diseases, particularly lysosomal storage disorders and immunodeficiencies. The company operates at clinical-stage scale with a concentrated pipeline in cell and gene therapy modalities.

Cell Therapy Gene Therapy

Profile data last refreshed 18h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Orchard Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Orchard Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

OTL-200

Lysosomal Storage Disease / Metachromatic Leukodystrophy

Growth

Lead asset in Phase 2/3 development; represents potential regulatory catalyst and inflection point for company value.

OTL-203

Mucopolysaccharidosis IH (Hurler Syndrome)

Help build intelligence for Orchard Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep expertise in cutting-edge gene therapy: OTL-200 and OTL-203 in Phase 2/3 for lysosomal storage diseases represent potential first-in-class opportunities in rare disease
Rare disease focus offers meaningful impact: treating ultra-rare genetic conditions (MPS-IH, ADA-SCID, beta-thalassemia) with limited therapeutic options provides high clinical and patient value
Public company stability with visa sponsorship: publicly traded status (Boston-based) with documented H1B approval (1 approval, 0 denials in 2023) provides career stability for international talent

Watch Out For

Zero current job openings: no active job count signals potential hiring freeze, restructuring, or company challenges that may limit near-term career movement
Early-stage pipeline with execution risk: all programs remain in Phase 1/2/3 with no marketed products, meaning no revenue base and potential cash burn concerns if clinical trials fail
Limited recent financial disclosure: absence of revenue, R&D spend, and cash position data indicates opaque financial health—raises questions about runway and sustainability

Pipeline & Clinical Trials

The Myelin Disorders Biorepository Project

Leukodystrophy

N/A

Imaging

Mucopolysaccharidoses

N/A

Clinical Trials (1)

NCT05354219Validation and Reliability of Iris Cameras in Mucopolysaccharidoses

N/A

Confirmatory Testing

Acid Sphingomyelinase Deficiency

N/A

Virtual Reality

Old Age; Debility

N/A

Clinical Trials (1)

NCT04083885Virtual Reality Training to Increase Rehabilitative Exercise in Seniors

N/A

Baby Detect : Genomic Newborn Screening

Congenital Adrenal Hyperplasia

N/A

OSSIX Volumax

Dental Implants

N/A

Clinical Trials (1)

NCT06187805Retrospective Case Series - OSSIX Volumax Collagen Xenograft Scaffolding

N/A

Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary

Neoplasms, Unknown Primary

N/A

Clinical Trials (1)

NCT02628379Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary

N/A

OTL-200 Gene Therapy

Lysosomal Storage Disease

PHASE_1_2

Clinical Trials (1)

NCT01560182Gene Therapy for Metachromatic Leukodystrophy (MLD)

Phase 1/2

Infusion of autologous EFS-ADA LV CD34+ cells

Adenosine Deaminase Deficiency

PHASE_1_2

Clinical Trials (1)

NCT01380990Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency

Phase 1/2

Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells

Severe Combined Immunodeficiency Due to ADA Deficiency

PHASE_1_2

Clinical Trials (1)

NCT02999984Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID

Phase 1/2

Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene

Beta-Thalassemia

PHASE_1_2

Clinical Trials (1)

NCT02453477Gene Therapy for Transfusion Dependent Beta-thalassemia

Phase 1/2

Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.

Mucopolysaccharidosis IH

PHASE_1_2

Clinical Trials (1)

NCT03488394Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler Variant

Phase 1/2

Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene

Mucopolysaccharidosis Type IIIA

PHASE_1_2

Clinical Trials (1)

NCT04201405Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA

Phase 1/2

Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells

Severe Combined Immunodeficiency Due to ADA Deficiency

PHASE_1_2

Clinical Trials (1)

NCT03765632Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID

Phase 1/2

Infusion of autologous EFS-ADA LV CD34+

ADA-SCID

PHASE_1_2

OTL-200

Lysosomal Storage Disease

PHASE_2

Clinical Trials (1)

NCT03392987A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)

Phase 2

Experimental: OTL-203

MPS-IH (Hurler Syndrome)

PHASE_3

Clinical Trials (1)

NCT06149403A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

Phase 3

OTL-200

Lysosomal Storage Diseases

PHASE_3

Clinical Trials (1)

NCT04283227OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)

Phase 3

Interview Prep Quick Facts

Founded: 2015

Portfolio: 14 clinical trials

Top TAs: Hematology, Oncology

H-1B (2023): 1 approval

Publications: 25 in PubMed

Therapeutic Area Focus

Hematology

1 pipeline

Oncology

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Metachromatic leukodystrophy (MLD) in France: the views of family caregivers on the diagnosis of the disease, its daily burden on their child, and the whole family.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie

2026

PMID:41760509

Restoration of progranulin by engineered hematopoietic stem cell-derived microglia corrects phenotypes of granulin knockout mice.

Orchard Therapeutics

About Orchard Therapeutics

Why Work Here

Key Products

Watch Out For

Pipeline & Clinical Trials

Recent News · Orchard Therapeutics(1)

Open Jobs (0)

Hiring Trend

Visa Sponsorship

Research Publications(10)